PMID- 3545428
OWN - NLM
STAT- MEDLINE
DCOM- 19870408
LR  - 20190619
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 59
IP  - 6
DP  - 1987 Mar 15
TI  - High dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for 
      allogeneic bone marrow transplantation for patients with acute leukemia.
PG  - 1083-6
AB  - A high dose combination chemotherapy regimen (CBV) consisting of cyclophosphamide 
      (1.5 gm/m2 day 1 to day 4); BCNU (300 mg/m2 day 1) and etoposide (100 mg/m2 every 
      12 hours for 6 doses), followed by bone marrow transplant from human leukocyte 
      antigen (HLA) identical sibling donors, was evaluated in 29 patients in whom 
      acute leukemia was in relapse or remission. Engraftment of donor cell type 
      occurred in all but one of 21 patients, in whom marker differences between donor 
      and recipient were established. Two of 11 patients transplanted during relapse of 
      the disease, lived beyond 1 year after bone marrow transplantation. One patient 
      died free of leukemia, 41 months after transplantation of meningitis. Two of 
      seven patients transplanted during the second remission of the disease, are alive 
      and free of leukemia at 42+, and 8+ months. All patients transplanted during the 
      third or fourth remission of the disease have died from either a further relapse, 
      or transplant related causes. The low incidence of organ toxicity with CBV allows 
      for further dose escalation of its drug components.
FAU - Zander, A R
AU  - Zander AR
FAU - Culbert, S
AU  - Culbert S
FAU - Jagannath, S
AU  - Jagannath S
FAU - Spitzer, G
AU  - Spitzer G
FAU - Keating, M
AU  - Keating M
FAU - Larry, N
AU  - Larry N
FAU - Cockerill, K
AU  - Cockerill K
FAU - Hester, J
AU  - Hester J
FAU - Horwitz, L
AU  - Horwitz L
FAU - Vellekoop, L
AU  - Vellekoop L
AU  - et al.
LA  - eng
GR  - CA-23077/CA/NCI NIH HHS/United States
GR  - CA-28153/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - L36H50F353 (Podophyllotoxin)
RN  - U68WG3173Y (Carmustine)
SB  - IM
MH  - Acute Disease
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
MH  - Bone Marrow Transplantation
MH  - Carmustine/administration & dosage
MH  - Combined Modality Therapy
MH  - Cyclophosphamide/administration & dosage
MH  - Humans
MH  - Leukemia/drug therapy/*therapy
MH  - Podophyllotoxin/administration & dosage
EDAT- 1987/03/15 00:00
MHDA- 1987/03/15 00:01
CRDT- 1987/03/15 00:00
PHST- 1987/03/15 00:00 [pubmed]
PHST- 1987/03/15 00:01 [medline]
PHST- 1987/03/15 00:00 [entrez]
AID - 10.1002/1097-0142(19870315)59:6<1083::aid-cncr2820590606>3.0.co;2-p [doi]
PST - ppublish
SO  - Cancer. 1987 Mar 15;59(6):1083-6. doi: 
      10.1002/1097-0142(19870315)59:6<1083::aid-cncr2820590606>3.0.co;2-p.